Gastroesophageal Reflux Disease Clinical Trial
Official title:
Gatekeeper® System Sham-Controlled Study for the Treatment of GERD
Verified date | July 2009 |
Source | MedtronicNeuro |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of the study is to demonstrate the intended use of the Gatekeeper Reflux Repair System to provide symptomatic relief is subjects with gastroesophageal reflux disease.
Status | Terminated |
Enrollment | 143 |
Est. completion date | June 2008 |
Est. primary completion date | June 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Diagnosis and main criteria for inclusion: - Subjects diagnosed with GERD with symptomatic improvement on PPIs. - Subjects who have demonstrated a baseline 24 Hour pH = 4% time with pH = 4.0. - Subjects with a baseline GERD-HRQL heartburn score of =11 on PPI and = 20 off PPI. Diagnosis and main criteria for exclusion: - Extensive Barrett's Esophagus (> 2 cm). - Esophagitis (LA Classification Grades C or D). - Previous history of gastroesophageal surgery, anti-reflux procedures, or gastroesophageal or gastric cancer. - Large hiatal hernia (> 3 cm). - Current complaints of clinical dysphagia evidenced by greater than one occurrence per month. - Esophageal strictures - Esophageal or gastric varices |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Netherlands | Contact Medtronic for specific site information | Amsterdam | |
United States | Contact Medtronic for specific site information | Atlanta | Georgia |
United States | Contact Medtronic for specific site information | Chicago | Illinois |
United States | Contact Medtronic for specific site information | Indianapolis | Indiana |
United States | Contact Medtronic for specific site information | Knoxville | Tennessee |
United States | Contact Medtronic for specific site information | Lebanon | New Hampshire |
United States | Contact Medtronic for specific site information | Lexington | Kentucky |
United States | Contact Medtronic for specific site information | Milwaukee | Wisconsin |
United States | Contact Medtronic for specific site information | New York | New York |
United States | Contact Medtronic for specific site information | San Francisco | California |
United States | Contact Medtronic for specific site information | St. Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
MedtronicNeuro |
United States, Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction in serious device and procedure related adverse device effects. | 6 months | ||
Secondary | Improvement in espophageal pH | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02135107 -
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
|
Phase 3 | |
Completed |
NCT01432392 -
Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Recruiting |
NCT01249482 -
Symptom Assessment for GERD Patients Receiving H. Pylori Eradication
|
N/A | |
Completed |
NCT01578642 -
Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease
|
Phase 2 | |
Completed |
NCT01200550 -
The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients
|
N/A | |
Completed |
NCT00998244 -
Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease
|
N/A | |
Unknown status |
NCT01128608 -
The Effect of High PCO2 Solution on Esophageal Acid Sensation
|
N/A | |
Completed |
NCT00978016 -
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
|
Phase 2 | |
Completed |
NCT00768196 -
Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients
|
N/A | |
Completed |
NCT00768443 -
Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)
|
N/A | |
Recruiting |
NCT00498082 -
Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease
|
N/A | |
Completed |
NCT00886197 -
Diagnostic Efficacy of Narrow Band Imaging in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT00378898 -
Feasibility of Placing Bravo PH Capsule in Proximal Esophagus
|
N/A | |
Completed |
NCT00507377 -
Foreshortened Esophagus and Its Surgical Therapy
|
||
Completed |
NCT00217347 -
Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy
|
N/A | |
Completed |
NCT00165022 -
Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population
|
N/A | |
Completed |
NCT00625495 -
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
|
Phase 4 | |
Completed |
NCT00214552 -
Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.
|
Phase 3 | |
Completed |
NCT00618150 -
Patient Education in Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT03299985 -
Diaphragmatic Myofascial Release in Gastroesophageal Reflux Disease
|
N/A |